Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Safe, rapid administration schedule for cis-platinum-mannitol

J M Rainey, D S Alberts

    Medical and Pediatric Oncology
    |January 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.

    Annals of oncology : official journal of the European Society for Medical Oncology·2013
    Same author

    Promising agents for chemoprevention of skin cancer.

    Current oncology (Toronto, Ont.)·2012
    Same author

    Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.

    Cancer causes & control : CCC·2012
    Same author

    Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.

    International journal of immunopathology and pharmacology·2011
    Same author

    Weight change during chemotherapy as a potential prognostic factor for stage III epithelial ovarian carcinoma: a Gynecologic Oncology Group study.

    Gynecologic oncology·2007
    Same author

    A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
    Same journal

    Kaposiform hemangioendothelioma and therapy with interferon-alpha.

    Medical and pediatric oncology·2003
    Same journal

    Importance of informed consent in offering to return research results to research participants.

    Medical and pediatric oncology·2003
    Same journal

    Tumor lysis syndrome and neuroblastoma.

    Medical and pediatric oncology·2003
    Same journal

    High incidence of brain tumors of childhood in Hungary between 1989 and 2001.

    Medical and pediatric oncology·2003
    Same journal

    Surviving childhood cancer: what next? Issues under consideration at the After Completion of Therapy (ACT) clinic in India.

    Medical and pediatric oncology·2003
    Same journal

    Local control in childhood extremity sarcomas: salvaging limbs and sparing function.

    Medical and pediatric oncology·2003
    See all related articles

    This study demonstrates a safe method for administering cis-diamminedichloroplatinum (II) (cisplatin). Patients receiving cisplatin therapy showed no elevated serum creatinine levels, indicating preserved kidney function.

    Area of Science:

    • Oncology
    • Nephrology
    • Pharmacology

    Background:

    • Cis-diamminedichloroplatinum (II) (cisplatin) is a widely used chemotherapy agent.
    • Nephrotoxicity is a significant concern associated with cisplatin administration.
    • Effective methods to mitigate cisplatin-induced kidney damage are crucial for patient management.

    Purpose of the Study:

    • To evaluate the safety and renal impact of a specific cisplatin administration protocol.
    • To determine if cisplatin, when administered with mannitol and fluids, affects serum creatinine levels.
    • To establish a safe and simple method for delivering cisplatin therapy.

    Main Methods:

    • Forty patients received cisplatin at doses ranging from 25-75 mg/m2.
    • Cisplatin was administered intravenously over 1-2 hours, accompanied by 40g mannitol and hydration.

    Related Experiment Videos

  • Serum creatinine levels were monitored throughout the treatment course.

    • Main Results:

    • No patients exhibited elevated serum creatinine levels, indicating no significant nephrotoxicity.
    • Cisplatin was administered at 50 mg/m2 to 22 patients and 75 mg/m2 to 6 patients.
    • Patients received 1-8 courses of therapy without any observed changes in renal function.

    Conclusions:

    • The described method of administering cisplatin with mannitol and fluids is safe.
    • This protocol effectively preserves kidney function during cisplatin chemotherapy.
    • A simple and safe administration method for cisplatin has been successfully achieved.